# US 2013/0158058 A1 · Hypercholesterolemia and tendinous injuries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158058 A1
- Document ID: US20130158058A1
- Status: Published application
- Kind: A1
- Application number: 13/767,515
- Filed: 2013-02-14
- Published: 2013-06-20
- Earliest claimed: 2008-01-31
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Joseph A. ABBOUD; Louis J. SOSLOWSKY
- Web page: https://patentgrep.com/patent/US20130158058A1

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/351: not condensed with another ring
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/47: Quinolines; Isoquinolines
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/10: Musculoskeletal or connective tissue disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury.

## Claims

### Claim 1

A method of treating a tendinous or musculoskeletal soft tissue injury, in a subject with hypercholesterolemia, comprising systemically administering to said subject with hypercholesterolemia a therapeutically effective amount of a cholesterol lowering agent, wherein said soft tissue injury is a tendon injury.

### Claim 2 (depends on 1)

The method of claim 1, wherein said tendinous injury is a rotator cuff injury, a knee tendon injury, a wrist tendon injury, an elbow tendon injury, a lateral epicondylitis, a medial epicondylitis, a flexor tendon injury, an extensor tendon injury, an achilles tendon injury, a patellar tendon injury, a peroneal tendon injury, a biceps tendon injury, or an overuse tendon injury.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cholesterol lowering agent is a statin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the statin is atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said subject with hypercholesterolemia has concentrations of TC higher than 240 mg/DL, HDL-C lower than 40 mg/DL, LDL-C higher than 130 mg/DL, or TG higher than 150 mg/DL in a serum sample from said subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein said subject with hypercholesterolemia has concentrations of TC higher than 240 mg/DL, HDL-C lower than 40 mg/DL, LDL-C higher than 130 mg/DL, and TG higher than 150 mg/DL in a serum sample from said subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein said statin lowers said subject's blood total cholesterol concentration below about 240 mg/dL.

### Claim 8 (depends on 6)

The method of claim 6, wherein said statin lowers said subject's blood LDL-C to below about 130 mg/DL.

### Claim 9 (depends on 6)

The method of claim 6, wherein said statin raises said subject's blood HDL-C to above about 40 mg/DL.

### Claim 10 (depends on 6)

The method of claim 6, wherein said statin lowers said subject's blood TG to below about 150 mg/DL.

### Claim 11 (depends on 1)

The method of claim 1, further comprising treating inflammation associated with said tendon injury.

### Claim 12 (depends on 1)

The method of claim 1, further comprising treating edema associated with said tendon injury.

### Claim 13 (depends on 1)

The method of claim 1, wherein treating said tendon injury comprises ameliorating symptoms associated with said tendon injury in said subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein treating said tendon injury comprises accelerating the healing of said tendon injury in said subject.

### Claim 15

A method of reducing the incidence of a tendinous or musculoskeletal soft tissue injury, in a subject with hypercholesterolemia and at risk of developing a tendon injury, comprising systemically administering to said subject with hypercholesterolemia a therapeutically effective amount of a cholesterol lowering agent, wherein said soft tissue injury is a tendon injury.

### Claim 16 (depends on 15)

The method of claim 15, wherein said tendon is a rotator cuff, a knee tendon, a wrist tendon, an elbow tendon, a flexor tendon, an extensor tendon, an achilles tendon, a patellar tendon, or a peroneal tendon.

### Claim 17 (depends on 15)

The method of claim 15, wherein said cholesterol lowering agent is a statin.

### Claim 18 (depends on 17)

The method of claim 17, wherein the statin is atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.

### Claim 19 (depends on 15)

The method of claim 15, wherein said subject with hypercholesterolemia has concentrations of TC higher than 240 mg/DL, HDL-C lower than 40 mg/DL, LDL-C higher than 130 mg/DL, or TG higher than 150 mg/DL in a serum sample from said subject.

### Claim 20 (depends on 15)

The method of claim 15, wherein said subject with hypercholesterolemia has concentrations of TC higher than 240 mg/DL, HDL-C lower than 40 mg/DL, LDL-C higher than 130 mg/DL, and TG higher than 150 mg/DL in a serum sample from said subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein said statin lowers said subject's blood total cholesterol concentration below about 240 mg/dL.

### Claim 22 (depends on 20)

The method of claim 20, wherein said statin lowers said subject's blood LDL-C to below about 130 mg/DL.

### Claim 23 (depends on 20)

The method of claim 20, wherein said statin raises said subject's blood HDL-C to above about 40 mg/DL.

### Claim 24 (depends on 20)

The method of claim 20, wherein said statin lowers said subject's blood TG to below about 150 mg/DL.

### Claim 25 (depends on 20)

The method of claim 20, wherein said subject at risk of developing a tendon injury is a subject who previously had said tendon injury and reducing the incidence of said tendon injury comprises reducing the risk of recurrence of said tendon injury.

### Claim 26 (depends on 20)

The method of claim 20, further comprises obtaining a serum sample from said subject;
determining the concentration of TC, HDL-C, LDL-C, TG or their combination in said sample; and comparing the concentration in said sample to a standard that comprises the concentrations of TC at 240 mg/DL, HDL-C at 40 mg/DL, LDL-C at 130 mg/DL, and TG at 150 mg/DL.
